1. US FDA. CDER Biomarker Qualification Program (2018). www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535922.htm#what-is
2. Temple RJ. A regulatory authority's opinion about surrogate end points. In: Clinical Measurement in Drug Evaluation. Nimmo WS, Tucker GT, (Eds). Wiley, NY, USA (1995).
3. US FDA. CDER Biomarker Qualification Program (2018). www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/ucm535882.htm
4. US FDA. Guidance for Industry and FDA Staff: Qualification for Drug Development Tools (2014). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
5. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization